Publication | Closed Access

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology